A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: Placebo
Drug: SM04690

Registration Number: NCT03727022

Lead Sponsor: Biosplice Therapeutics, Inc.

Brief Summary: The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study is to provide an initial evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL injection) approximately six months apart into the target knee of moderately to severely symptomatic osteoarthritis (OA) subjects. Subjects who complete this 52-week long study will be eligible to enter the extension phase for an additional 52 weeks of treatment.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 102

Inclusion Criteria

Males and females between 40 and 80 years of age, inclusive, in general good health
Ambulatory
Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at Screening Visit 1 (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis)
Pain compatible with OA of the knee(s) for at least 26 weeks prior to Screening Visit 1
Primary source of pain throughout the body is due to OA in the target knee
Daily OA knee pain diary average NRS intensity score ≥ 4 and ≤ 8 in the target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
Pain NRS scores recorded for the target knee on at least 4 out of the 7 days immediately preceding Day 1
Daily OA knee pain diary average NRS intensity score < 4 in the non-target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
Pain NRS scores recorded for the non-target knee on at least 4 out of the 7 days immediately preceding Day 1
WOMAC pain subscore of 20-40 (out of 50) and WOMAC physical function subscore of 68-136 (out of 170) for the target knee at baseline, regardless of if the subject is on symptomatic oral treatment (baseline questionnaire completed during the screening period prior to randomization)
Widespread Pain Index (WPI) score of ≤ 4 and a Symptom Severity Question 2 (SSQ2) score of ≤ 2 at Screening Visit 1
Willingness to use an electronic diary on a daily basis in the evening for the screening period and 104-week study duration
Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, benzodiazepine, methaqualone, and tricyclic antidepressants, except if any such drugs are clinically indicated and allowed by the protocol, at Screening Visit 1.
Subjects with depression or anxiety must be clinically stable for 12 weeks prior to Screening Visit 1 in the opinion of the Investigator and, if on treatment for depression or anxiety, be on 12 weeks of stable therapy
Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
Subjects must have read and understood the Informed Consent Form (ICF), and must have signed and dated it prior to any study-related procedure being performed
Subject's Screening Visit 1 visit must occur while enrollment into the study is open
Subject is able to have a Screening Visit 2 qCT image acquired that does not require a re-scan as determined by the central imaging vendor

Exclusion Criteria

Pregnant and breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) and have a positive or indeterminate pregnancy result at Screening Visit 2 or Day 1
Women who are not post-menopausal or permanently surgically sterile, who are sexually active, and who are not willing to use birth control (as outlined in Section 5.3.1) during the study period
Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or who are not using birth control as outlined in Section 5.3.1
Body mass index (BMI) > 35
Partial or complete joint replacement in either knee
Currently requires:
1. regular use (in the opinion of the Investigator) of ambulatory assistive devices (e.g., wheelchair, parallel bars, walker, canes, or crutches), or
2. use of a lower extremity prosthesis, and/or a structural knee brace (i.e., a knee brace that contains hardware)
Radiographic disease Stage 0, 1, or 4 in the target knee at Screening Visit 1 according to the Kellgren-Lawrence grading of knee OA as assessed by independent central readers
Previous enrollment in a Samumed clinical trial investigating SM04690
Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Screening Visit 1
Any bone fracture(s) within 26 weeks prior to Screening Visit 1
Any surgery scheduled during the study period. Non-surgical invasive procedures conducted for a diagnostic or therapeutic purpose scheduled during the study period are not prohibited.(refer to section 7.6)
Significant and clinically evident misalignment of either knee that would impact subject function, as determined by the Investigator
History of malignancy within the last 5 years; however, subjects with prior history of in situ basal or squamous cell skin cancer are eligible if completely excised. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to Screening Visit 1
Clinically significant abnormal screening hematology values, blood chemistry values, or urinalysis values as determined by the Investigator
Any condition, including laboratory findings not included in the Screening Visit 2 laboratory tests and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
Comorbid conditions that could affect study endpoint assessments of the target knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
Other conditions that, in the opinion of the Investigator, could affect study endpoint assessments of either knee, including, but not limited to, peripheral neuropathy (e.g., diabetic neuropathy), symptomatic hip osteoarthritis, symptomatic degenerative disc disease, and patellofemoral syndrome
History of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder
Participation in a clinical research trial that included the receipt of an investigational product (IP) or any experimental therapeutic procedure within 26 weeks prior to Screening Visit 1, or planned participation in any such trial
Treatment of the target knee with intra-articular glucocorticoids (e.g., methylprednisolone) within 12 weeks prior to Screening Visit 1
Any intra-articular injection into the target knee with a therapeutic aim including, but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma (PRP), and stem cell therapies within 24 weeks prior to Screening Visit 1; treatment of the target knee with intra-articular glucocorticoids greater than 12 weeks prior to Screening Visit 1 is allowed
Treatment with systemic (oral, intramuscular, or intravenous)glucocorticoids greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to Screening Visit 1
Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Screening Visit 1
Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Screening Visit 1 (refer to Appendix 1)
Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at Day 1
Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of centrally acting analgesics (e.g., duloxetine) (refer to Appendix 1) within 12 weeks prior to Screening Visit 1
Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of anticonvulsants (not listed in Appendix 1 ) within 12 weeks prior to Screening Visit 1, unless used for seizure or migraine prophylaxis
Subjects requiring the usage of opioids >1x per week within 12 weeks prior to Screening Visit 1
Topical local anesthetic agents (gels, creams, or patches such as the Lidoderm patch) used for the treatment of knee OA within 7 days of Screening Visit 1
Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy in the opinion of the Investigator. In addition, subjects with an HbA1c >9 at Screening Visit 2 will be excluded.
If on NSAIDs for the treatment of OA pain, subjects who have not maintained a stable regimen in the opinion of the Investigator at Screening Visit 1
Any contraindications for performing DXA scans of the hips or spine including but not limited to:
1. other radiological investigations using contrast media or radionuclides within 7 days of Screening Visit 2
2. weight that precludes scanning at these sites
Subjects who have had a single or bilateral hip replacement
Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at any investigative site, or are directly affiliated with the study at any investigative site
Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study, or who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of said employees responsible for the conduct of the study
Subject has non-evaluable DXA scans of the hips or spine (i.e., pins, screws, any surgical implant, fracture, or severe degenerative changes in the region of interest), as assessed by the central imaging vendor at the time of screening

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vehicle	Placebo	Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
0.07 mg SM04690	SM04690	Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle

Primary Outcome Measures

Name	Time	Method
Safety of SM04690 treatment: adverse events (AEs) and serious adverse events (SAEs)	Baseline through Week 52	Evaluate the safety of SM04690 treatment by the occurrence of AEs and SAEs.
Change in BMD from baseline in the treated knee compared to placebo by qCT	Baseline, and Week 52	Evaluate change in bone mineral density (BMD) from baseline in the treated knee compared to placebo by quantitative computed tomography (qCT)

Secondary Outcome Measures

Name	Time	Method
Change in a serum cartilage biomarker COMP from baseline	Baseline through Week 52	Evaluate change in serum cartilage biomarker (e.g., cartilage oligomeric matrix protein \[COMP\]) from baseline
Change from baseline OA pain in the target knee (WOMAC pain subscore)	Baseline through Week 52	Evaluate change from baseline OA pain in the target knee as assessed by subject-reported monthly Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 20.
Change from baseline OA function in the target knee (WOMAC physical function subscore)	Baseline through Week 52	Evaluate change from baseline OA function in the target knee as assessed by subject-reported monthly WOMAC physical function subscore (WOMAC Function). The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 68.
Change in BMD from baseline in the treated knee compared to placebo by qCT	Baseline and Weeks 12, 24 and 36	Evaluate change in BMD from baseline in the treated knee compared to placebo by qCT
Change in serum bone biomarker β-CTX from baseline	Baseline through Week 52	Evaluate change in serum bone biomarker β-C-terminal telopeptide \[β-CTX\] from baseline
Change in serum bone biomarker PINP from baseline	Baseline through Week 52	Evaluate change in serum bone biomarker N-terminal propeptide of procollagen type I \[PINP\] from baseline
Change from baseline OA pain in the target knee (NRS)	Baseline through Week 52	Evaluate change from baseline OA pain in the target knee at each week as assessed by the weekly averages of subject-reported daily pain Numeric Rating Scale (NRS). The pain NRS is an 11-point scale \[0-10\] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain.
Change from baseline OA disease activity	Baseline through Week 52	Evaluate change from baseline OA disease activity as assessed by subject-reported monthly Patient Global Assessment. The Patient Global Assessment is an 11-point \[0-10\] Numeric Rating Scale \[NRS\] on which the subjects will rate how they feel their target knee OA is doing, considering all the ways in which their target knee OA may affect them. The NRS is anchored by descriptors at each end ("Very Good" on the left and "Very Bad" on the right).
Change in BMD from baseline by DXA of the spine and hips	Baseline, and Weeks 24 and 52	Evaluate change in BMD from baseline by dual-energy X-ray absorptiometry (DXA) of the spine and hips
Change from baseline in medial joint space width (mJSW) of the target knee	Baseline, Weeks 24 and 52	Evaluate change from baseline in medial joint space width (mJSW) as documented by radiograph of the target knee.
Difference in the change in BMD from baseline between the treated and untreated knee by qCT	Baseline and Weeks 12, 24, 36 and 52	Evaluate difference in the change in BMD from baseline between the treated and untreated knee by qCT